Alsumali A, Chemaly RF, Graham J, Jiang Y, Merchant S, Miles L, Schelfhout J, Yang J, Tang Y. Cost-effectiveness analysis of cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients from a US payer perspective. J Med Virol. 2021 Jun;93(6):3786-94. doi: 10.1002/jmv.26462
Davis AE, Brogan AJ, Goodwin B, Nocea G, Lozano V. Short-term cost and efficiency analysis of raltegravir versus atazanavir/ritonavir or darunavir/ritonavir for treatment-naive adults with HIV-1 infection in Spain. HIV Clin Trials. 2017 Nov;18(5-6):214-22. doi: 10.1080/15284336.2017.1402144
Coon CD, Bokowy KL, Horblyuk R, Zisman RS, McLeod LD, Brown MT. The development and initial assessment of the strategy and leadership systems capability evaluation survey. Health Care Manag (Frederick). 2012 Oct 1;31(4):332-41.
Trask PC, Mitra D, Iyer S, Candrilli SD, Kaye JA. Patterns and prognostic indicators of response to CML treatment in a multi-country medical record review study. Int J Hematol. 2012 May 1;95(5):535-44.
Mitra D, Trask PC, Iyer S, Candrilli SD, Kaye JA. Patient characteristics and treatment patterns in chronic myeloid leukemia: evidence from a multi-country retrospective medical record chart review study. Int J Hematol. 2012 Mar 1;95(3):263-73.
Brogan AJ, Mrus J, Hill A, Sawyer AW, Smets E. Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States. HIV Clin Trials. 2010 May;11(3):133-44.
Pelletier SJ, Fu S, Thyagarajan (Hoffman) V, Romero-Marrero C, Batheja MJ, Punch JD, Magee JC, Lok AS, Fontana RJ, Marrero JA. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. Liver Transpl Surg. 2009 Aug;15(8):859-68. doi: 10.1002/lt.21778